Published 22 June 2009, doi:10.1136/bmj.b2521
Cite this as: BMJ 2009;338:b2521

News

German agency refuses to rule on drug’s benefits until Pfizer discloses all trial results

Ned Stafford

1 Hamburg

The first 150 words of the full text of this article appear below.

An independent scientific institute that conducts healthcare research and evaluations mainly on behalf of Germany’s public health insurance regulator has accused the drug giant Pfizer of "concealing" research data on its depression treatment reboxetine.

The Institute for Quality and Efficiency in Health Care, which is based in Cologne and known in Germany as IQWiG, contends that Pfizer has refused to provide a complete list of all published and unpublished trials of reboxetine, which was approved in 1997 in Germany and marketed by Pfizer as Edronax.

If the institute says it is unable to assess the benefit of the drug because of lack of data, it is likely that health insurance companies in Germany may refuse to reimburse its cost.

"Deception through concealment is no trivial offence," said the institute’s director, Peter Sawicki. "By concealing study data, the manufacturer is depriving patients and doctors of the opportunity to make an informed . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Rationing new medicines in the UK
Michael Drummond and Anne Mason
BMJ 2009 338: a3182. [Extract] [Full Text]

Rapid Responses:

Read all Rapid Responses

Government freedom of information provisions and clinical trial data
Malcolm B Gillies
bmj.com, 23 Jun 2009 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ